A head-to-head comparison of risankizumab and ixekizumab for genital psoriasis: a real-life, 24-week, prospective study.
Elena SotiriouKaterina BakirtziIlias PapadimitriouAikaterini TsentemeidouP EftychidouV EleftheriadisAimillios LallasDemetrios IoannidesE VakirlisPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2021)